This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hologic to Buy Cytyc for $6.2 Billion

Hologic (HOLX - Get Report) is acquiring Cytyc (CYTC) in a $6.2 billion cash-and-stock deal.

The two companies, which specialize in health care products for women, announced the transaction Sunday in a joint press release.

Bedford, Mass.-based Hologic will exchange 0.52 shares of its common stock and $16.50 in cash for each share of Cytyc common stock. Based on Hologic's Friday closing price of $57.61, that represents a payment of $46.46 for each Cytyc share and a 32% premium to Cytyc's Friday closing level of $35.05.

Hologic predicts that the acquisition will add more than 10 cents to its adjusted earnings per share in the first year after its close and will be "significantly more accretive" thereafter.

Upon the deal's completion, Hologic shareholders would own approximately 45 percent of the combined company, and Cytyc shareholders would own approximately 55 percent.

Boards of both companies have approved the transaction, which is expected to be completed in the third quarter of this year.

Under the terms of the deal, Cytyc will become a wholly owned subsidiary of Hologic. Hologic will maintain its headquarters in Bedford and Cytyc's offices in Marlborough, Mass., where the latter company is currently headquartered.

According to the press release, the combined company will have direct operations in over 20 countries with more than 3,300 employees, including 1,200 sales and service professionals.

Hologic makes diagnostic and medical imaging systems for women. Cytyc makes diagnostic and surgical products covering a range of cancer and women's health applications including cervical cancer screening and radiation treatment of early-stage breast cancer.

The companies plan to hold a conference call at 8:30 a.m. EDT Monday to discuss the deal.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
HOLX $33.98 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs